- Home
- RXRX vs PTY Comparison
RXRX vs PTY Comparison
Compare RXRX & PTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RXRX
- PTY
- Stock Information
- Founded
- RXRX 2013
- PTY 2002
- Country
- RXRX United States
- PTY United States
- Employees
- RXRX N/A
- PTY N/A
- Industry
- RXRX Biotechnology: Pharmaceutical Preparations
- PTY Investment Managers
- Sector
- RXRX Health Care
- PTY Finance
- Exchange
- RXRX Nasdaq
- PTY Nasdaq
- Market Cap
- RXRX 2.4B
- PTY 2.6B
- IPO Year
- RXRX 2021
- PTY N/A
- Fundamental
- Price
- RXRX $5.77
- PTY $13.98
- Analyst Decision
- RXRX Buy
- PTY
- Analyst Count
- RXRX 5
- PTY 0
- Target Price
- RXRX $7.00
- PTY N/A
- AVG Volume (30 Days)
- RXRX 24.9M
- PTY 550.4K
- Earning Date
- RXRX 08-05-2025
- PTY 01-01-0001
- Dividend Yield
- RXRX N/A
- PTY 9.65%
- EPS Growth
- RXRX N/A
- PTY N/A
- EPS
- RXRX N/A
- PTY N/A
- Revenue
- RXRX $64,596,000.00
- PTY N/A
- Revenue This Year
- RXRX $19.96
- PTY N/A
- Revenue Next Year
- RXRX $61.39
- PTY N/A
- P/E Ratio
- RXRX N/A
- PTY N/A
- Revenue Growth
- RXRX 30.14
- PTY N/A
- 52 Week Low
- RXRX $3.79
- PTY $11.92
- 52 Week High
- RXRX $12.36
- PTY $14.88
- Technical
- Relative Strength Index (RSI)
- RXRX 53.41
- PTY 57.51
- Support Level
- RXRX $5.41
- PTY $13.73
- Resistance Level
- RXRX $5.82
- PTY $14.09
- Average True Range (ATR)
- RXRX 0.32
- PTY 0.06
- MACD
- RXRX -0.04
- PTY -0.00
- Stochastic Oscillator
- RXRX 52.78
- PTY 42.50
About RXRX Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
About PTY Pimco Corporate & Income Opportunity Fund
PIMCO Corporate & Income Opportunity Fds operates as a closed-end management investment company. It seeks to maximize total return through a combination of current income and capital appreciation. The fund invests a majority of the total assets in a combination of corporate debt obligations of varying maturities, other corporate income-producing securities, and income-producing securities of non-corporate issuers, such as U.S. Government securities, municipal securities, and mortgage-backed and other asset-backed securities issued on a public or private basis.